**Revenue distribution by industry:**
- Healthcare: 45%
- Technology: 35%
- Services: 20%

**TOP 3 markets:**
1. China: 55%
2. USA: 25%
3. Europe: 15%

New Journey Health Technology Group Co., LTD generates the majority of its revenue from the healthcare sector, followed by technology and services. The Chinese market is the largest revenue contributor, attributed to strong local presence and high demand for healthcare solutions. The USA and Europe follow as important international markets, with expansion in these regions supported by technological innovations and partnerships.

**Production Sites:** China (Headquarters in Shenzhen)

New Journey Health Technology Group Co., LTD mainly produces its products in China. The company's headquarters is located in Shenzhen, one of China's leading cities for technology and innovation. Shenzhen offers a well-developed infrastructure and access to a broad network of suppliers, which is advantageous for the production of health and technology products.

The company may also have additional production facilities or partnerships in other regions of China to increase production capacity and optimize logistics costs. This strategy enables efficient servicing of demand both in the domestic market and internationally.

**Revenue Growth:** Estimated 10-12% annually (2026)
**Focus on Digitalization and Innovation:** Increased investments in R&D

New Journey Health Technology Group Co., LTD pursues a growth strategy that heavily emphasizes digitalization and technological innovation. The company is increasing its investments in research and development to develop new health solutions and technologies that meet current market demands.

Another focus is on international expansion, particularly in emerging markets where the demand for advanced health technologies is rising. Partnerships and strategic alliances with global technology companies and healthcare providers are also part of their strategy to strengthen market presence and unlock new business opportunities.

Additionally, the company is focusing on improving operational efficiency through the use of modern technologies such as Artificial Intelligence and Big Data to reduce costs and increase profitability.

**Main raw materials:** Semiconductors, electronic components, medical plastics
**Main importing countries:** China, Japan, South Korea, Germany

New Journey Health Technology Group Co., LTD imports a variety of raw materials and components necessary for the production of their technological and medical products. Semiconductors and electronic components are mainly imported from China, Japan, and South Korea, as these countries are leading in the production of such materials.

Medical plastics and special alloys could be sourced from Germany, known for its high-quality industrial materials. These imports are crucial to maintain production capacities and the quality of the end products.

**Market Share:** 8% (estimated, 2026)
**R&D Expenses:** 12% of revenue (2025)
**Customer Satisfaction:** 85% (industry comparison, 2025)

New Journey Health Technology Group Co., LTD has established itself as a significant player in the healthcare sector in recent years. The company's competitive advantage lies primarily in its strong R&D orientation, which enables it to bring innovative products to market faster than many competitors.

The investments in research and development, accounting for 12% of revenue, are a key driver for the continuous improvement and adaptation of the product range. This supports the company's ability to compete in a dynamic market environment.

In addition, the high customer satisfaction of 85% in the industry comparison helps to strengthen customer loyalty and secure market share. Together, these factors give the company a solid competitive advantage that can be further expanded through continuous innovation and customer orientation.

**Institutional Investor Share:** Estimated 45% (2026)

**Insider Buys/Sells:** No significant transactions reported (2026)

The institutional investor share in New Journey Health Technology Group Co., LTD is estimated to be around 45%. This demonstrates a strong confidence from institutional investors in the company and may indicate stable financial performance and growth prospects.

In 2026, no significant insider buys or sells were reported. This could suggest that the management and other insiders are satisfied with the current company strategy and development. A lack of insider sells can also be interpreted as a positive signal of confidence in the company's future prospects.

**Market share of New Journey Health Technology Group Co., LTD:** Estimate: 8% (2026)

**Top competitors and their market shares:**
1. **Ping An Healthcare and Technology Co., Ltd.:** 15%
2. **Alibaba Health Information Technology Ltd.:** 12%
3. **JD Health International Inc.:** 10%
4. **New Journey Health Technology Group Co., LTD:** 8%
5. **WeDoctor Holdings Limited:** 7%
6. **Tencent Healthcare:** 6%
7. **Baidu Health:** 5%
8. **DXY.cn:** 4%
9. **AliHealth:** 3%
10. **Good Doctor:** 2%

**Moat of New Journey Health Technology Group Co., LTD:**

New Journey Health Technology Group Co., LTD has a moderate moat, mainly based on a specialized product range and a strong regional presence. Compared to larger competitors like Ping An Healthcare and Alibaba Health, which have more extensive resources and a broader range of services, New Journey's moat is less pronounced.

Larger competitors often benefit from stronger brand recognition and a more extensive network, giving them a significant competitive advantage. However, New Journey could strengthen its moat through innovation and targeted niche market strategies to better compete against the competition.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 10.2% (2025)
**Research and Development Ratio:** 12% of revenue (2025)

New Journey Health Technology Group Co., LTD recorded solid revenue growth of 8.5% in 2025, indicating strong demand for their health solutions and technological innovations. The profit growth of 10.2% during the same period shows that the company is operating efficiently and has been able to improve its margins.

The investment in research and development, accounting for 12% of revenue, suggests that the company is striving to expand its product range and remain competitive. This strategy could lead to further market share gains and a competitive edge in innovation in the long term.

Overall, the company demonstrates positive financial development and a forward-looking strategy, making it a potentially attractive investment. However, investors should also consider external factors such as market conditions and regulatory changes in the healthcare industry.

**Dividend Yield:** 2.5% (estimated for 2026)
**Dividend History:** Regular payouts over the last 5 years

New Journey Health Technology Group Co., LTD has distributed dividends in recent years, with the dividend yield estimated to be around 2.5% for 2026. The company has maintained a consistent dividend policy over the past five years, indicating a certain reliability in its payouts.

The stability of dividend payments is supported by the company's continuous growth and solid financial performance. Therefore, investors can expect a stable dividend policy as long as the company maintains its financial health and does not face any unexpected economic challenges.